Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

The Effect of HLA-B27 on Susceptibility and Severity of COVID-19

James T. Rosenbaum, Hedley Hamilton, Michael H. Weisman, John D. Reveille, Kevin L. Winthrop and Dongseok Choi
The Journal of Rheumatology April 2021, 48 (4) 621-622; DOI: https://doi.org/10.3899/jrheum.200939
James T. Rosenbaum
1Departments of Medicine, Ophthalmology, and Cell Biology, Oregon Health & Science University, Portland, Oregon, USA;
2Legacy Devers Eye Institute, Portland, Oregon, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James T. Rosenbaum
  • For correspondence: rosenbaj@ohsu.edu
Hedley Hamilton
3Any-3, London, UK;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael H. Weisman
4Cedars Sinai Medical Center, Los Angeles, California, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael H. Weisman
John D. Reveille
5Department of Medicine, University of Texas, Houston, Texas, USA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin L. Winthrop
6OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kevin L. Winthrop
Dongseok Choi
6OHSU-PSU School of Public Health and Departments of Medicine and Ophthalmology, Oregon Health & Science University, Portland, Oregon, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dongseok Choi
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Although many genes have polymorphisms, major histocompatibility complex genes are the most polymorphic. Many assume that the diversity of HLA increases the likelihood that a species can survive pandemics. Indeed, evidence suggests that HLA-B27 is protective for HIV1, hepatitis C2, and possibly influenza3. We recently reported results of a Web-based survey involving patients with spondyloarthritis (SpA)4. We now report an additional analysis of these data obtained between April 10, 2020, and May 31, 2020, to determine if the genetic marker HLA-B27 influences the contracting of the coronavirus 2019 (COVID-19) or the severity of COVID-19 infection.

Subjects who participated in this research provided electronic consent as a first step in completing the survey. As it was a survey, it was not practical to obtain written, informed consent. Institutional review board approval was received from Oregon Health & Science University (IRB approval number: 00021375).

Subjects (n = 3435) from 65 countries diagnosed with SpA completed the survey. Of these, 2836 or 82.6% were aware of their HLA-B27 status, with 76.1% being positive. Of those with known HLA-B27 status, 74.5% were from the United States and 8.0% were from Canada. The median age was 52 years. The group aware of B27 status included 1806 women, 1015 men, and 15 nonbinary. Interestingly, 82.9% of male respondents were HLA-B27+ compared to 72.2% of female respondents. It has been previously noted that women with ankylosing spondylitis (AS) are less likely to be B27+ compared to men5. Table 1 shows the specific diagnoses and the HLA-B27 status for each diagnosis. Subjects with acute anterior uveitis had the highest percentage who were known to be B27-positive (calculated on the basis of only those who knew their B27 status) at 87.4%. Surprisingly, AS at 79.3% was slightly less likely to be associated with HLA-B27 than reactive arthritis, but the survey included relatively few with reactive arthritis. As expected, fewer with nonradiographic axial SpA were HLA-B27–positive (65.8%) compared to AS. Crohn disease, ulcerative colitis, and psoriasis are not associated with HLA-B27. However, a high percentage of respondents with one of these diagnoses was HLA-B27–positive. This high percentage undoubtedly reflects the nature of the survey and meant that anyone with one of these diagnoses also had SpA.

View this table:
  • View inline
  • View popup
Table 1

Diagnoses included in survey and relation to HLA-B27.

Forty-one subjects reported having COVID-19, although only 18 reported testing positive. Many reporting agencies now announce presumed as well as confirmed cases since PCR testing is not universal. Ten of 679 B27-negative subjects (1.5%) believed they had had COVID-19, whereas 31 of 2157 B27-positive subjects believed that they had COVID-19 (1.4%). This difference is not significantly different by the chi-square test (P = 0.112). If one restricts the analysis to those with a positive test for the virus, the result was 0.6% for either B27-negative or B27-positive subjects.

We assessed COVID-19 severity on a subjective scale ranging from 1 (mild) to 10 (life-threatening) and found no significant effect from B27, whether the analysis was based on confirmed or suspected cases. The distribution of COVID-19 severity based on suspected cases is shown in Table 2.

View this table:
  • View inline
  • View popup
Table 2

Effect of B27 status on subjective severity of symptoms attributed to COVID-19*.

There were only 5 hospitalizations among the respondents: 1 of 679 who was HLA-B27–negative and 4 of the 2157 who were HLA-B27–positive. This difference is also not statistically significant.

The extensive polymorphism of the HLA system is thought to result from the need for a species to be immunologically diverse in order to survive a pandemic. HLA-B27 confers some protection against HIV3 and hepatitis C4. However, it does not appear to protect against severe acute respiratory syndrome6,7, which like COVID-19, is attributable to coronavirus. Our data are consistent with another recent study, which did not report on spondylitis specifically, but relative to other rheumatic diseases, spondylitis did not appear to confer unique susceptibility or result in greater severity from COVID-198. We believe that ours is the first study to specifically address the consequences of being HLA-B27–positive in relation to this infection.

This study has several limitations. Although we surveyed a large number of patients with SpA, we identified a relatively small number of subjects with a confirmed COVID-19 infection. However, the rate of infection among our US respondents, 5.69 cases per 1000 people, is very comparable to the expected rate in the United States of 5.35 cases per 1000 as of May 31, 2020. Thus, while our observations should be replicated and confirmed, they are consistent with expected values for the United States as a whole. Second, we tested for the effect of HLA-B27 in the context of SpA. Although we do not currently suspect that SpA or the medications taken for SpA affect the likelihood of developing COVID-194,8,9, it is possible that a study on healthy HLA-B27 individuals might find differences not detectable with our methodology. Finally, only HLA-B27 alleles could be analyzed, and other HLA-B alleles have been shown to influence the risk for AS, such as B*38 and B*4010. These alleles should be further examined for potential effect on COVID-19. We are collecting longitudinal data on the subjects in this study to gain more information as to how HLA-B27–related disease affects COVID-19 susceptibility or severity.

ACKNOWLEDGMENT

We are grateful to Kimberly Ogle for assistance with Institutional Review Board approval. Cassie Shafer, Richard Howard, and Elin Aslanyan contributed to the design of the questionnaire.

Footnotes

  • This work was supported by the Spondylitis Association of America and Any3. The Spondylitis Association of America receives support from AbbVie for this project. Dr. Rosenbaum receives support from the Grandmaison Fund for Autoimmunity Research, the William and Mary Bauman Foundation, the Stan and Madelle Rosenfeld Family Trust, and Research to Prevent Blindness. JTR consults for AbbVie, Gilead, UCB, Novartis, Roche, Horizon, Santen, Eyevensys, Corvus, Affibody; he receives royalties from UpToDate; he receives grant support from Pfizer. HH owns Any-3, the website that hosted the survey and donated its services. MHW consults for Novartis, UCB, Gilead, and GSK. JDR consults for UCB; he receives research support from Lilly and Janssen. KLW consults for Pfizer, AbbVie, UCB, Lilly, Galapagos, GSK, Roche, and Gilead; he receives research support from BMS and Pfizer. None of the authors believe that the above relationships influenced the contents of this report.

  • Copyright © 2021 by the Journal of Rheumatology

REFERENCES

  1. 1.↵
    1. Hendel H,
    2. Caillat-Zucman S,
    3. Lebuanec H,
    4. Carrington M,
    5. O’Brien S,
    6. Andrieu JM, et al.
    New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS. J Immunol 1999;162:6942-6.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Fitzmaurice K,
    2. Hurst J,
    3. Dring M,
    4. Rauch A,
    5. McLaren PJ,
    6. Gunthard HF, et al; Irish HCV Research Consortium; Swiss HIV Cohort Study
    . Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut 2015;64:813-9.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Boon AC,
    2. De Mutsert G,
    3. Fouchier RA,
    4. Sintnicolaas K,
    5. Osterhaus AD,
    6. Rimmelzwaan GF
    . Preferential HLA usage in the influenza virus-specific CTL response. J Immunol 2004;172:4435-43.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Rosenbaum JT,
    2. Hamilton H,
    3. Choi D,
    4. Weisman MH,
    5. Reveille JD,
    6. Winthrop KL
    . Biologics, spondylitis and COVID-19. Ann Rheum Dis 2020 Jun 10 (E-pub ahead of print).
  5. 5.↵
    1. van der Horst-Bruinsma IE,
    2. Zack DJ,
    3. Szumski A,
    4. Koenig AS
    . Female patients with ankylosing spondylitis: analysis of the impact of gender across treatment studies. Ann Rheum Dis 2013;72:1221-4.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Lin M,
    2. Tseng HK,
    3. Trejaut JA,
    4. Lee HL,
    5. Loo JH,
    6. Chu CC, et al.
    Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003;4:9.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Yuan FF,
    2. Velickovic Z,
    3. Ashton LJ,
    4. Dyer WB,
    5. Geczy AF,
    6. Dunckley H, et al.
    Influence of HLA gene polymorphisms on susceptibility and outcome post infection with the SARS-CoV virus. Virol Sin 2014;29:128-30.
    OpenUrl
  8. 8.↵
    1. Gianfrancesco M,
    2. Hyrich KL,
    3. Al-Adely S,
    4. Carmona L,
    5. Danila MI,
    6. Gossec L, et al.
    Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2020;79:859-66.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Haberman R,
    2. Axelrad J,
    3. Chen A,
    4. Castillo R,
    5. Yan D,
    6. Izmirly P, et al.
    Covid-19 in immune-mediated inflammatory diseases - case series from New York. N Engl J Med 2020;383:85-8.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Reveille JD,
    2. Zhou X,
    3. Lee M,
    4. Weisman MH,
    5. Yi L,
    6. Gensler LS, et al.
    HLA class I and II alleles in susceptibility to ankylosing spondylitis. Ann Rheum Dis 2019;78:66-73.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 4
1 Apr 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
James T. Rosenbaum, Hedley Hamilton, Michael H. Weisman, John D. Reveille, Kevin L. Winthrop, Dongseok Choi
The Journal of Rheumatology Apr 2021, 48 (4) 621-622; DOI: 10.3899/jrheum.200939

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
James T. Rosenbaum, Hedley Hamilton, Michael H. Weisman, John D. Reveille, Kevin L. Winthrop, Dongseok Choi
The Journal of Rheumatology Apr 2021, 48 (4) 621-622; DOI: 10.3899/jrheum.200939
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • COVID-19 Vaccination as a Trigger of IgA Vasculitis: Truth or Illusion?
  • Drs. Ramdani and Audemard-Verger reply
  • Further Simplified Clinimetry Using a Multidimensional Health Assessment Questionnaire
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire